-
1
-
-
0033576816
-
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
-
Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults.N Engl J Med 1999; 341:1865-1873.
-
(1999)
N Engl J Med
, vol.341
, pp. 1865-1873
-
-
Staszewski, S.1
Morales-Ramirez, J.2
Tashima, K.T.3
Rachlis, A.4
Skiest, D.5
Stanford, J.6
-
2
-
-
84875886913
-
-
Accessed 7 April 2010
-
DHHS guidelines. http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail. aspx?GuidelineID&7 [Accessed 7 April 2010].
-
DHHS Guidelines
-
-
-
3
-
-
84856071427
-
-
Accessed 7 April 2010
-
EACS recommendations. http://www.europeanaidsclinicalsociety.org/ guidelines.asp [Accessed 7 April 2010].
-
EACS Recommendations
-
-
-
4
-
-
0007895376
-
-
DuPont Pharmaceuticals Efavirenz: DuPont Pharmaceuticals
-
DuPont Pharmaceuticals. Product Information Sustiva. Efavirenz: DuPont Pharmaceuticals; 1998.
-
(1998)
Product Information Sustiva
-
-
-
5
-
-
0035423911
-
Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz
-
Mart́nez E, Rousaud A, Blanco JL, Garća-Viejo MA, Peri JM, Mallolas J, et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr 2001; 27:336-343. (Pubitemid 32729079)
-
(2001)
Journal of Acquired Immune Deficiency Syndromes
, vol.27
, Issue.4
, pp. 336-343
-
-
Blanch, J.1
Martinez, E.2
Rousaud, A.3
Blanco, J.-L.4
Garcia-Viejo, M.-A.5
Peri, J.-M.6
Mallolas, J.7
De Lazzari, E.8
De Pablo, J.9
Gatell, J.M.10
-
7
-
-
28144452516
-
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals
-
Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005; 143:714-721.
-
(2005)
Ann Intern Med
, vol.143
, pp. 714-721
-
-
Clifford, D.B.1
Evans, S.2
Yang, Y.3
Acosta, E.P.4
Goodkin, K.5
Tashima, K.6
-
8
-
-
0036499964
-
Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens
-
Fumaz CR, Tuldrà A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, et al. Quality of life, emotional status and adherence in patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 2002; 29:244-253. (Pubitemid 34208532)
-
(2002)
Journal of Acquired Immune Deficiency Syndromes
, vol.29
, Issue.3
, pp. 244-253
-
-
Fumaz, C.R.1
Tuldra, A.2
Ferrer, Ma.J.3
Paredes, R.4
Bonjoch, A.5
Jou, T.6
Negredo, E.7
Romeu, J.8
Sirera, G.9
Tural, C.10
Clotet, B.11
-
9
-
-
20244378824
-
Long-term neuropsychiatric disorders on efavirenz-based approaches: Quality of life, psychologic issues, and adherence
-
DOI 10.1097/01.qai.0000147523.41993.47
-
Fumaz CR, Muñoz-Moreno JA, Moltó J, Negredo E, Ferrer MJ, Sirera G, Pérez-Alvarez N, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues and adherence. J Acquir Immune Defic Syndr 2005; 38:560-565. (Pubitemid 40524478)
-
(2005)
Journal of Acquired Immune Deficiency Syndromes
, vol.38
, Issue.5
, pp. 560-565
-
-
Fumaz, C.R.1
Munoz-Moreno, J.A.2
Molto, J.3
Negredo, E.4
Ferrer, M.J.5
Sirera, G.6
Perez-Alvarez, N.7
Gomez, G.8
Burger, D.9
Clotet, B.10
-
10
-
-
35348995999
-
Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
-
DOI 10.1016/S1473-3099(07)70262-1, PII S1473309907702621
-
Mehta U, Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect Dis 2007; 7:733-738. (Pubitemid 47600092)
-
(2007)
Lancet Infectious Diseases
, vol.7
, Issue.11
, pp. 733-738
-
-
Mehta, U.1
Maartens, G.2
-
11
-
-
34347348060
-
No patient left behind-better treatments for resistant HIV infection
-
DOI 10.1016/S0140-6736(07)61022-8, PII S0140673607610228
-
Hirschel B, Perneger T. No patient left behind: better treatments for resistant HIV infection. Lancet 2007; 370:3-5. (Pubitemid 47017448)
-
(2007)
Lancet
, vol.370
, Issue.9581
, pp. 3-5
-
-
Hirschel, B.1
Perneger, T.2
-
12
-
-
75149175071
-
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials
-
for the SWITCHMRK 1 and 2 investigators
-
Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al.; for the SWITCHMRK 1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396-407.
-
(2010)
Lancet
, vol.375
, pp. 396-407
-
-
Eron, J.J.1
Young, B.2
Cooper, D.A.3
Youle, M.4
Dejesus, E.5
Andrade-Villanueva, J.6
-
13
-
-
78650306222
-
A randomized crossover study to compare efavirenz and etravirine treatment
-
Swiss HIV Cohort Study
-
Nguyen A, Calmy A, Delhumeau C, Mercier IK, Cavassini M, Fayet-Mello A, Elzi L, Swiss HIV Cohort Study. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS 2011; 25:57-63.
-
(2011)
AIDS
, vol.25
, pp. 57-63
-
-
Nguyen, A.1
Calmy, A.2
Delhumeau, C.3
Mercier, I.K.4
Cavassini, M.5
Fayet-Mello, A.6
Elzi, L.7
-
14
-
-
17144385842
-
Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry
-
DOI 10.1016/j.jchromb.2005.02.010
-
Colombo S, Beguin A, Telenti A, Biollaz J, Buclin T, Rochat B, et al. Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819:259-276. (Pubitemid 40521961)
-
(2005)
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
, vol.819
, Issue.2
, pp. 259-276
-
-
Colombo, S.1
Beguin, A.2
Telenti, A.3
Biollaz, J.4
Buclin, T.5
Rochat, B.6
Decosterd, L.A.7
-
15
-
-
58149134503
-
Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction
-
Fayet A, Béguin A, de Tejada BM, Colombo S, Cavassini M, Gerber S, et al. Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit 2008; 30:511-522.
-
(2008)
Ther Drug Monit
, vol.30
, pp. 511-522
-
-
Fayet, A.1
Béguin, A.2
De Tejada, B.M.3
Colombo, S.4
Cavassini, M.5
Gerber, S.6
-
16
-
-
63249093621
-
A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine
-
Fayet A, Béguin A, Zanolari B, Cruchon S, Guignard N, Telenti A, et al. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:1057-1069.
-
(2009)
J Chromatogr B Analyt Technol Biomed Life Sci
, vol.877
, pp. 1057-1069
-
-
Fayet, A.1
Béguin, A.2
Zanolari, B.3
Cruchon, S.4
Guignard, N.5
Telenti, A.6
-
17
-
-
0003586930
-
-
Manual for the Depression Anxiety Stress Scales (DASS) Sydney, Australia: University of New South Wales
-
Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales (DASS). Psychology Foundation Monograph. Sydney, Australia: University of New South Wales; 1993.
-
(1993)
Psychology Foundation Monograph
-
-
Lovibond, S.H.1
Lovibond, P.F.2
-
18
-
-
0031021390
-
Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples
-
DOI 10.1016/S0005-7967(96)00068-X
-
Brown TA, Chorpita BF, Korotitsch W, Barlow DH. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. Behav Res Ther 1997; 1:79-89. (Pubitemid 27026171)
-
(1997)
Behaviour Research and Therapy
, vol.35
, Issue.1
, pp. 79-89
-
-
Brown, T.A.1
Chorpita, B.F.2
Korotitsch, W.3
Barlow, D.H.4
-
19
-
-
0026333617
-
A new method for measuring daytime sleepiness: The Epworth sleepiness scale
-
Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14:540-545.
-
(1991)
Sleep
, vol.14
, pp. 540-545
-
-
Johns, M.W.1
-
20
-
-
0015877495
-
Quantification of sleepiness: A new approach
-
Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. Psychophysiology 1973; 10:431-436.
-
(1973)
Psychophysiology
, vol.10
, pp. 431-436
-
-
Hoddes, E.1
Zarcone, V.2
Smythe, H.3
Phillips, R.4
Dement, W.C.5
-
22
-
-
33748340844
-
Validation of the revised 10-item HIV treatment satisfaction questionnaire status version and new change version
-
DOI 10.1111/j.1524-4733.2006.00121.x
-
Woodcock A, Bradley C. Validation of the Revised 10-Item HIV Treatment Satisfaction Questionnaire Status Version and New Change Version. Value Health 2006; 9:320-333. (Pubitemid 44337785)
-
(2006)
Value in Health
, vol.9
, Issue.5
, pp. 320-333
-
-
Woodcock, A.1
Bradley, C.2
-
23
-
-
0037256015
-
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
-
DOI 10.1067/mcp.2003.22
-
Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2003; 73:20-30. (Pubitemid 36158483)
-
(2003)
Clinical Pharmacology and Therapeutics
, vol.73
, Issue.1
, pp. 20-30
-
-
Csajka, C.1
Marzolini, C.2
Fattinger, K.3
Decosterd, L.A.4
Fellay, J.5
Telenti, A.6
Biollaz, J.7
Buclin, T.8
-
24
-
-
33845366857
-
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
-
DOI 10.1097/QAI.0b013e31802b4956, PII 0012633420061215000002
-
Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43:509-515. (Pubitemid 44885615)
-
(2006)
Journal of Acquired Immune Deficiency Syndromes
, vol.43
, Issue.5
, pp. 509-515
-
-
Markowitz, M.1
Morales-Ramirez, J.O.2
Nguyen, B.-Y.3
Kovacs, C.M.4
Steigbigel, R.T.5
Cooper, D.A.6
Liporace, R.7
Schwartz, R.8
Isaacs, R.9
Gilde, L.R.10
Wenning, L.11
Zhao, J.12
Teppler, H.13
Tsoukas, C.14
Galpin, J.15
Hicks, C.16
Brown, S.17
Chen, J.18
Miller, M.19
Hazuda, D.20
Vacca, J.21
Iwamoto, M.22
Rowley, M.23
Summa, V.24
more..
-
25
-
-
0035875828
-
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
-
DOI 10.1097/00002030-200101050-00011
-
Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001; 15:71-75. (Pubitemid 32055781)
-
(2001)
AIDS
, vol.15
, Issue.1
, pp. 71-75
-
-
Marzolini, C.1
Telenti, A.2
Decosterd, L.A.3
Greub, G.4
Biollaz, J.5
Buclin, T.6
-
26
-
-
28044459173
-
Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring
-
DOI 10.1086/497835
-
Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005; 41:1648-1653. (Pubitemid 41691605)
-
(2005)
Clinical Infectious Diseases
, vol.41
, Issue.11
, pp. 1648-1653
-
-
Gutierrez, F.1
Navarro, A.2
Padilla, S.3
Anton, R.4
Masia, M.5
Borras, J.6
Martin-Hidalgo, A.7
-
27
-
-
67649236216
-
The nucleoside backbone affects durability of efavirenz-or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals
-
Annan NT, Nelson M, Mandalia S, Bower M, Gazzard BG, Stebbing J. The nucleoside backbone affects durability of efavirenz-or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals. J Acquir Immune Defic Syndr 2009; 51:140-146.
-
(2009)
J Acquir Immune Defic Syndr
, vol.51
, pp. 140-146
-
-
Annan, N.T.1
Nelson, M.2
Mandalia, S.3
Bower, M.4
Gazzard, B.G.5
Stebbing, J.6
-
28
-
-
78650309812
-
Efavirenz: What happens in the long term?
-
Swaden L, Sabin CA, Lampe FC, Youle MS, Johnson MA, Lipman M. Efavirenz: what happens in the long term? BHIVA Conf 2003; 9:O9.
-
(2003)
BHIVA Conf
, vol.9
-
-
Swaden, L.1
Sabin, C.A.2
Lampe, F.C.3
Youle, M.S.4
Johnson, M.A.5
Lipman, M.6
-
29
-
-
47949120697
-
Raltegravir with optimized background therapy for resistant HIV-1 infection
-
BENCHMRK Study Teams
-
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al., BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
-
(2008)
N Engl J Med
, vol.359
, pp. 339-354
-
-
Steigbigel, R.T.1
Cooper, D.A.2
Kumar, P.N.3
Eron, J.E.4
Schechter, M.5
Markowitz, M.6
-
30
-
-
77954348583
-
Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study
-
SPIRAL Study Group
-
Mart́nez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, et al., SPIRAL Study Group. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24:1697-1707.
-
(2010)
AIDS
, vol.24
, pp. 1697-1707
-
-
Mart́nez, E.1
Larrousse, M.2
Llibre, J.M.3
Gutiérrez, F.4
Saumoy, M.5
Antela, A.6
|